| International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium AC Harris, R Young, S Devine, WJ Hogan, F Ayuk, U Bunworasate, ... Biology of Blood and Marrow Transplantation 22 (1), 4-10, 2016 | 702 | 2016 |
| An early-biomarker algorithm predicts lethal graft-versus-host disease and survival MJ Hartwell, U Özbek, E Holler, AS Renteria, H Major-Monfried, P Reddy, ... JCI insight 2 (3), 2017 | 243 | 2017 |
| MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD H Major-Monfried, AS Renteria, A Pawarode, P Reddy, F Ayuk, E Holler, ... Blood, The Journal of the American Society of Hematology 131 (25), 2846-2855, 2018 | 197 | 2018 |
| Acute graft-versus-host disease of the gut: considerations for the gastroenterologist S Naymagon, L Naymagon, SY Wong, HM Ko, A Renteria, J Levine, ... Nature Reviews Gastroenterology & Hepatology 14 (12), 711-726, 2017 | 159 | 2017 |
| Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors SG Holtan, N Khera, JE Levine, X Chai, B Storer, HD Liu, Y Inamoto, ... Blood, The Journal of the American Society of Hematology 128 (19), 2350-2358, 2016 | 53 | 2016 |
| Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation YB Chen, NN Shah, AS Renteria, C Cutler, J Jansson, M Akbari, C Chen, ... Blood Advances 3 (23), 4136-4146, 2019 | 50 | 2019 |
| Amphiregulin modifies the Minnesota acute graft-versus-host disease risk score: results from BMT CTN 0302/0802 SG Holtan, TE DeFor, A Panoskaltsis-Mortari, N Khera, JE Levine, ... Blood advances 2 (15), 1882-1888, 2018 | 33 | 2018 |
| A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease Y Fløisand, MA Schroeder, P Chevallier, D Selleslag, S Devine, ... Bone marrow transplantation 56 (10), 2477-2488, 2021 | 18 | 2021 |
| Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma SS Kim, AS Renteria, A Steinberg, K Banoff, L Isola Cytotherapy 16 (11), 1584-1589, 2014 | 17 | 2014 |
| Multiple myeloma, race, insurance and treatment H Joshi, S Lin, K Fei, AS Renteria, H Jacobs, M Mazumdar, S Jagannath, ... Cancer epidemiology 73, 101974, 2021 | 16 | 2021 |
| Role of minimal residual disease in the management of acute myeloid leukemia—A case-based discussion A Coltoff, J Houldsworth, A Keyzner, AS Renteria, J Mascarenhas Annals of Hematology 97, 1155-1167, 2018 | 16 | 2018 |
| Where you live can impact your cancer risk: a look at multiple myeloma in New York City GR Kamath, AS Renteria, S Jagannath, EJ Gallagher, S Parekh, ... Annals of epidemiology 48, 43-50. e4, 2020 | 14 | 2020 |
| Development of a biomarker scoring system for use in graft-versus-host disease AS Renteria, JE Levine, JL Ferrara Biomarkers in medicine 10 (8), 793-795, 2016 | 9 | 2016 |
| Anterolateral papillary muscle rupture caused by myocardial infarction: A case report S Jayawardena, AS Renteria, O Burzyantseva, G Lokesh, L Thelusmond Cases Journal 1, 1-4, 2008 | 7 | 2008 |
| Simultaneous PRES and TMA secondary to tacrolimus after allogeneic bone marrow transplant DB Aruch, A Renteria Blood, The Journal of the American Society of Hematology 125 (25), 3963-3963, 2015 | 5 | 2015 |
| Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis B Freeman, D Brauneis, DC Seldin, K Quillen, JM Sloan, AS Renteria, ... Bone marrow transplantation 49 (10), 1345-1346, 2014 | 5 | 2014 |
| Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease AS Renteria, JE Levine, JLM Ferrara Expert opinion on orphan drugs 4 (5), 469-484, 2016 | 4 | 2016 |
| AML with BCR-ABL1 fusion treated with imatinib, a hypomethylating agent and venetoclax SK Low, S Nanua, M Patel, AS Renteria Leukemia Research Reports 17, 100333, 2022 | 3 | 2022 |
| A phase 1b study of intravenous vedolizumab plus standard of care for graft-versus-host disease prophylaxis in subjects undergoing allogeneic hematopoietic stem cell … YB Chen, NN Shah, AS Renteria, CS Cutler, J Jansson, M Akbari, C Chen, ... Blood 132, 605, 2018 | 3 | 2018 |
| Amphiregulin improves stratification of the refined minnesota acute graft-versus-host disease risk score: results from BMT CTN 0302/0802 SG Holtan, TE DeFor, J Pidala, N Khera, SJ Lee, A Howard, J Wu, ... Blood 130, 72, 2017 | 3 | 2017 |
